Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Collplant Holdings ( (CLGN) ) has provided an announcement.
On April 15, 2025, CollPlant Biotechnologies announced that its Collink.3D® BioInks align with the FDA’s recent initiative to phase out animal testing in drug development. These BioInks offer a human-relevant alternative for preclinical safety studies, potentially reducing costs and time to market. The FDA’s plan, revealed on April 10, 2025, aims to replace animal testing with New Approach Methodologies (NAMs), which CollPlant’s products support by enabling the biofabrication of tissue-on-a-chip systems. This development is expected to enhance drug safety, lower research costs, and accelerate drug evaluations, benefiting stakeholders across the pharmaceutical industry.
Spark’s Take on CLGN Stock
According to Spark, TipRanks’ AI Analyst, CLGN is a Underperform.
Collplant Holdings is currently experiencing significant financial difficulties, with sharp declines in revenue and cash flow, and substantial net losses. The technical indicators suggest ongoing negative momentum, and the valuation is unattractive due to persistent losses. While the earnings call offered some optimism with promising product developments and a solid cash runway, these are overshadowed by the financial challenges. The overall score reflects these concerns, indicating a high-risk investment.
To see Spark’s full report on CLGN stock, click here.
More about Collplant Holdings
CollPlant Biotechnologies is a regenerative and aesthetic medicine company focused on developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics. The company is involved in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, and has a development and commercialization agreement with Allergan, an AbbVie company, for dermal and soft tissue fillers.
YTD Price Performance: -35.70%
Average Trading Volume: 8,207
Technical Sentiment Signal: Buy
Current Market Cap: $28.06M
See more insights into CLGN stock on TipRanks’ Stock Analysis page.